ClinicalTrials.gg
Active, not recruitingNCT07035093TRIUMPH-7Updated Sep 25, 2026

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

A Phase 3 interventional study of Retatrutide and Placebo in Obesity, Overweight and Chronic Low Back Pain (CLBP), sponsored by Eli Lilly and Company. Active, not recruiting at 40 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Planned enrollment
7th of 16
586 · median 392
Started
2025
with 2 others
Phase 3
9 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is one of 9 in phase 3, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

03

Conditions studied

  • Obesity
  • Overweight
  • Chronic Low Back Pain (CLBP)

Keywords

  • Axial Predominant Low Back Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a history of axial-predominant low back pain
  • Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
  • Have a (BMI) ≥27 kilograms per square meter (kg/m2) at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • Have a non-axial origin low back pain
  • Have had botulinum or injections to the spine within 1 year of screening
  • Have had trigger point injection to the spine within 6 months of screening
  • Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days prior to screening
  • Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening
  • Have a prior or planned surgical treatment for obesity
  • Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
586 participants (estimated)

Study arms

  • Experimental
    Retatrutide

    Participants will receive Retatrutide subcutaneously (SC)

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive Placebo SC

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Pain Intensity Per Numeric Rating Scale

    Time frame: Baseline, up to 72 weeks

  2. Percent Change from Baseline in Body Weight

    Time frame: Baseline, up to 72 weeks

Secondary outcomes

  1. Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale

    Time frame: Baseline, up to 72 weeks

  2. Number of Participants with Reduction in Body Weight

    Time frame: Baseline, up to 72 weeks

  3. Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS)

    Time frame: Baseline, up to 72 weeks

  4. Change in Pain Interference as Measured by PROMIS

    Time frame: Baseline, up to 72 weeks

  5. Change in Sleep as Measured by PROMIS

    Time frame: Baseline, up to 72 weeks

  6. Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2)

    Time frame: Baseline, up to 72 weeks

  7. Change in Waist Circumference

    Time frame: Baseline, up to 72 weeks

  8. Change in Biomarkers of Inflammation as Measured by Blood Test

    Time frame: Baseline, up to 72 weeks

  9. Change in Blood Pressure

    Time frame: Baseline, up to 72 weeks

  10. Change in Glycemic Control

    Time frame: Baseline, up to 72 weeks

  11. Percent Change in Total Cholesterol

    Time frame: Baseline, up to 72 weeks

  12. Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)

    Time frame: Baseline, up to 72 weeks

07

Study locations

40 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 28 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 24, 2025
StartActual
May 29, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07035093
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
May 29, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion